Christina T. Loguidice

ONS kicked off with a lively parade, which included over 100 nurses representing 16 countries from all over the globe.

Radon is an invisible, odorless, and tasteless radioactive gas that is released into the air or dissolves into groundwater as uranium in rocks or soil decays.

Palonosetron (Aloxi) is the only 5-HT3 receptor antagonist approved for treatment of delayed chemotherapy-induced nausea and vomiting (CINV) following administration of moderately emetogenic chemotherapeutic agents.

ON JANUARY 27, APPLE INTRODUCED THE iPad, touting it as "a revolutionary device for browsing the Web, reading and sending email, enjoying photos, watching videos, listening to music, playing games, reading e-books, and much more."

Dating can be a terrifying and frustrating endeavor, especially if you are shy or socially awkward. It may seem impossible to even meet someone when you find yourself struggling to muster up the courage to initiate a conversation.

Radiation therapy has been used to treat cancer for more than 100 years, and was made possible by the discovery of X-rays in 1895 by German physicist Wilhelm Conrad Röntgen, which allowed tumors to be detected more easily and noninvasively.

Cloud computing, or the storage of data on the Internet, is taking off at a rapid pace, with numerous start-ups and established entities vying for consumer attention and amassing considerable user bases very quickly.

Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and most feared side effects of chemotherapy.

During the the National Comprehensive Cancer Network 15th Annual Conference, updates were presented for various NCCN Clinical Practice Guidelines.

NCCN is increasingly collaborating with other nations to develop foreign editions of its guidelines.

Some patients with ovarian cancer benefit from adding a taxane to a platinum-based chemotherapy, but the regimen presents increased risk.

George Somlo, MD, City of Hope Comprehensive Cancer Center, presented the updates to the NCCN Multiple Myeloma Guidelines.

These new guidelines were presented by Lee M. Krug, MD, Memorial Sloan-Kettering Cancer Center.

A combination regimen of docetaxel and carboplatin prolongs PFS in recurrent ovarian cancer but decreases quality of life.

This year's updates parse sarcomas, emphasize the importance of accurate pathology evaluations, and examine the value of molecular testing.

At NCCN, B. Douglas Smith, MD, presented updates to the NCCN Acute Myeloid Leukemia Guidelines.

At NCCN, David Ettinger, MD, presented updates to the NCCN Occult Primary Guidelines.

An NCCN panel reviewed changes to the NCCN Breast Cancer Guidelines for invasive breast cancer.

A study shows that XELOX improves disease-free survival rates for elderly patients with advanced-staged colorectal cancer.

Patients with these two variations experienced recurrence more than three times sooner than those without it.

Sunitinib, approved to treat renal cell carcinoma and gastrointestinal stromal tumors, boosts survival rates in patients with neuroendocrine pancreatic tumors.

A novel blood test identifies PAM4 (or clivatuzumab), an antigen that is present in almost 90% of pancreatic cancers and precancers.

To improve early detection of colorectal cancer and adenomas, when survival chances are greatest, researchers tried develop a reliable blood test for detection.

Radon is an invisible, odorless, and tasteless radioactive gas that is released into the air or dissolves into groundwater as uranium in rocks or soil decays. It was classified as a human carcinogen in 1988 by the International Agency for Research on Cancer, but the ill health effects of this invisible killer had been observed for centuries in Europe.

Digital pens are finding a place in healthcare and are poised to leave their mark on medicine.

Data from the fully enrolled REVEAL-1 trial presented at the 51st ASH Annual Meeting showed single-agent voreloxin, an investigational drug, to be a safe and effective treatment in elderly patients with treatment-naïve acute myeloid leukemia (AML).

Current treatments for chronic lymphocytic leukemia (CLL) can be damaging to the immune system, leaving patients vulnerable to infections, which is the primary cause of death for many patients with CLL. According to a study presented at the 51st Annual American Society of Hematology Meeting, a new oral agent called 17-DMAG may avoid this problem. Mouse models assessing 17-DMAG showed this agent to be highly selective for CLL cells, while having minimal effect on normal immune cells, suggesting the agent leaves the immune system intact.

New Orleans, LA - Although studies have shown plerixafor (Mozobil) plus granulocyte-colony stimulating factor (G-CSF) mobilizes more CD34+ cells than G-CSF alone prior to autologous hematopoietic stem cell transplant, many patients receive chemotherapy followed by G-CSF to mobilize CD34+ cells before transplantation. In a poster session presented at the 51st ASH Annual Meeting, Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Transplant, Texas Transplant Institute, San Antonio, Texas, reported the results of a retrospective study that found plerixafor plus G-CSF mobilization resulted in more predictable days of collection, no weekend apheresis procedures, and no unscheduled hospital admissions compared with chemotherapy plus G-CSF.

During the 51st ASH Annual Meeting, several new data from the PROPEL trial were released, including updates on the ORR and safety of pralatrexate in patients with PTCL and data on the correlation between baseline methylmalonic acid status and mucositis severity in this population. While the data reinforce pralatrexate as a viable treatment in patients with relapsed or refractory PTCL, some question whether the drug confers enough of a benefit to warrant its $30,000 per month cost.